Navigation Links
China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
Date:11/30/2009

CHANGCHUN, China and LOS ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; 'China Yongxin Pharmaceuticals' or 'the Company'), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced it has completed preparation for distribution of medicines on the Essential Drug List.

The Chinese government recently formalized the nation's Essential Drug List which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China in August 18, 2009. According to the Chinese government's healthcare reform plan, 90 percent of China's citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List will be purchased and distributed to medical facilities including hospitals, clinics, pharmacies, etc. All drugs on the List will be covered by the basic insurance plan supported by the government. The government will invite public bidding for centralized distribution for essential drugs. Currently, Yongxin distributes 297 products out of 307 drugs listed on EDL. As one of the top medicine distributors in Jilin province with modern pharmaceutical logistic center, China Yongxin launched corresponding business preparation for public bidding and distribution for the first batch of 138 township hospitals and 11 city hospitals in Jilin province. The official public bidding is expected to be announced before the end of 2009. The winning of first batch will increase revenues of drug distribution and will help facilitate winning other batches of hospitals.

"We are pleased to initiate distribution of essential drugs and believe this presents a significant growth opportunity. The government's new efforts to centralize distribution of essential drugs will benefit China Yongxin in the long-term since we are one of the leading drug distributors in Northeastern China," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin. "With our modern logistic center, state-of-art ERP system and experienced distribution team, we are well positioned to capitalize this opportunity and contribute to our growth in 2010 and beyond"

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .

Forward Looking Statements

This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

     Mr. Sam Liu, COO
     China Yongxin Pharmaceuticals, Inc.
     Tel:   +1-626-581-9098
     Email: info@yongxinchina.com

SOURCE China Yongxin Pharmaceuticals, Inc.


'/>"/>
SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 This market research report on ... future prospects of the market in terms of revenue ... engaged in the manufacture of microbiology culture media and ... a market snapshot providing the overall information of various ... This section also provides the overall information and data ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists and  ... Experiences SHPG ) ... of children born with rare diseases, as well as the future ... a new initiative designed to positively affect the lives of children ... disease care. --> To mark the company,s founding 30 ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... PLYMOUTH MEETING, Pa. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... place of standard bone cement products to prevent infection ... a question that the experts at ECRI Institute have ... Cement: Fighting Infection or Fighting Your Bottom Line?" ... or Fighting Your Bottom Line?" --> ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
Breaking Biology News(10 mins):